These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

281 related items for PubMed ID: 6577943

  • 1. Potentiation of 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity by 2,3-dihydro-1H-imidazolo[1,2-b]pyrazole in the human promyelocytic leukemic cell, HL-60.
    Grant S, Bhalla K, Rauscher F, Cadman E.
    Cancer Res; 1983 Nov; 43(11):5093-100. PubMed ID: 6577943
    [Abstract] [Full Text] [Related]

  • 2. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-beta-D- arabinofuranosylcytosine.
    Bhalla K, Nayak R, Grant S.
    Cancer Res; 1984 Nov; 44(11):5029-37. PubMed ID: 6091869
    [Abstract] [Full Text] [Related]

  • 3. Schedule-dependent enhancement of 1-beta-D-arabinofuranosylcytosine incorporation into HL-60 DNA by deoxyguanosine.
    Ross DD, Akman SA, Joneckis CC, Yang E, Bachur NR.
    Cancer Res; 1984 Apr; 44(4):1530-5. PubMed ID: 6584206
    [Abstract] [Full Text] [Related]

  • 4. Potentiation of cytotoxicity of 1-beta-D-arabinofuranosylcytosine for K562 human leukemic cells by cadeguomycin.
    Suzuki H, Kim SH, Tanara M, Okazaki K, Okabe T, Wu RT, Tanaka N.
    Cancer Res; 1987 Feb 01; 47(3):713-7. PubMed ID: 3467840
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Metabolism, incorporation into DNA, and interactions with 1-beta-D-arabinofuranosylcytosine of 5-hydroxymethyl-2'-deoxyuridine in human promyelocytic leukemia cells (HL-60).
    Vilpo JA, Vilpo LM.
    Cancer Res; 1988 Jun 01; 48(11):3117-22. PubMed ID: 3163271
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. The effect of a prolonged in vitro exposure to 1-beta-D arabinofuranosylcytosine and deoxycytidine on the survival of normal (CFU-GM) and leukemic (L-CFU) human myeloid progenitor cells in suspension culture.
    Grant S, Bhalla K, Arlin Z, Howe CW.
    Exp Hematol; 1990 Jan 01; 18(1):41-8. PubMed ID: 2298268
    [Abstract] [Full Text] [Related]

  • 10. Direct relationship of marrow cell growth and 1-beta-D-arabinofuranosylcytosine metabolism.
    Karp JE, Donehower RC, Dole GB, Burke PJ.
    Cancer Res; 1984 Nov 01; 44(11):5046-50. PubMed ID: 6488163
    [Abstract] [Full Text] [Related]

  • 11. Formation of 1-beta-D-arabinofuranosylcytosine diphosphate choline in cultured human leukemic RPMI 6410 cells.
    Lauzon GJ, Paran JH, Paterson AR.
    Cancer Res; 1978 Jun 01; 38(6):1723-9. PubMed ID: 274174
    [Abstract] [Full Text] [Related]

  • 12. Modulation of 1-[beta-D-arabinofuranosyl] cytosine-induced apoptosis in human myeloid leukemia cells by staurosporine and other pharmacological inhibitors of protein kinase C.
    Grant S, Turner AJ, Bartimole TM, Nelms PA, Joe VC, Jarvis WD.
    Oncol Res; 1994 Jun 01; 6(2):87-99. PubMed ID: 7949469
    [Abstract] [Full Text] [Related]

  • 13. Modulation of 1-beta-D-arabinofuranosylcytosine metabolism and cytotoxicity in L1210 cells by fluoropyrimidine pretreatment.
    Grant S, Cadman E.
    Cancer Res; 1982 Sep 01; 42(9):3550-6. PubMed ID: 6213294
    [Abstract] [Full Text] [Related]

  • 14. Potential for selective enhancement of the in vivo metabolism of 1-beta-D-arabinofuranosylcytosine in rats by thymidine pretreatment.
    Danhauser LL, Rustum YM.
    Cancer Res; 1985 May 01; 45(5):2002-7. PubMed ID: 3986756
    [Abstract] [Full Text] [Related]

  • 15. Effects of 1-beta-D-arabinofuranosylcytosine on DNA replication intermediates monitored by pH-step alkaline elution.
    Ross DD, Chen SR, Cuddy DP.
    Cancer Res; 1990 May 01; 50(9):2658-66. PubMed ID: 2328491
    [Abstract] [Full Text] [Related]

  • 16. Quantitation of 1-beta-D-arabinofuranosylcytosine 5'-triphosphate in the leukemic cells from bone marrow and peripheral blood of patients receiving 1-beta-D-arabinofuranosylcytosine therapy.
    Plunkett W, Hug V, Keating MJ, Chubb S.
    Cancer Res; 1980 Mar 01; 40(3):588-91. PubMed ID: 6937239
    [Abstract] [Full Text] [Related]

  • 17. Effect of the interval between exposures to cytarabine on its cytotoxic action on HL-60 myeloid leukemic cells.
    Leclerc JM, Momparler RL.
    Cancer Treat Rep; 1984 Sep 01; 68(9):1143-8. PubMed ID: 6592037
    [Abstract] [Full Text] [Related]

  • 18. Mechanism of synergistic cell killing by hydroxyurea and cytosine arabinoside.
    Tanaka M, Kimura K, Yoshida S.
    Jpn J Cancer Res; 1985 Aug 01; 76(8):729-35. PubMed ID: 3930450
    [Abstract] [Full Text] [Related]

  • 19. Enhancement of the toxicity and DNA incorporation of arabinosyl-5-azacytosine and 1-beta-D-arabinofuranosylcytosine by cyclopentenyl cytosine.
    Grem JL, Allegra CJ.
    Cancer Res; 1990 Nov 15; 50(22):7279-84. PubMed ID: 1699659
    [Abstract] [Full Text] [Related]

  • 20. Schedule-dependent synergy and antagonism between high-dose 1-beta-D-arabinofuranosylcytosine and asparaginase in the L5178Y murine leukemia.
    Schwartz SA, Morgenstern B, Capizzi RL.
    Cancer Res; 1982 Jun 15; 42(6):2191-7. PubMed ID: 7074600
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.